Proving the economic advantages of decentralized trials

Download “Making The Economic Case For Decentralized Clinical Trials”

Although the popularity of the decentralized clinical trial (DCT) model is on the rise and its benefits in improving patient-centricity and streamlining major trial tasks are well-known, sponsors can still be wary, wondering if DCTs can really elevate their bottom line.

Citeline, in partnership with ICON, explores the results of a recent Tufts Center for the Study of Drug Development study quantifying the financial value of DCTs based on three key performance indicators (KPIs). Access this revealing analysis of the true economic viability of the decentralized clinical trial model.

Whitepaper

Complete the form below to download the content.

* - marks a required field

Email Address

First Name

Last Name

Address

City

Country

Province

State

Post Code

Phone

Answer the following questions about your organization below:

Company Name

How many people are employed by your organization?

What is your company's revenue?

In which industry do you work?

Job Function

Job Title

Job Level

Department

By clicking ‘Submit’ you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.